TA 6666

Drug Profile

TA 6666

Alternative Names: TA-6666

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 12 May 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)
  • 12 May 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top